Skip to main content

Did you know that there can be a host living in your eyelashes?

If you weren’t aware, let’s introduce you to it: It’s called Demodex, a tiny mite. In most cases, Demodex is a natural part of our skin’s microbiome and is kept in check by our immune system. However, in some instances, it may cause certain conditions.

Generally, Demodex is harmless. Nevertheless, an infestation can lead to problems such as ocular rosacea, recurring styes, or blepharitis (eyelid inflammation). If you experience symptoms like eyelash dandruff, eye dryness, a sensation of foreign particles in your eye, redness, or irritation, Demodex could be the culprit.

XDEMVY Targets and Kills the Mites

A Solution for Demodex Blepharitis (DB)

Fortunately, XDEMVY was specifically created to treat Demodex blepharitis (DB).

Notably, XDEMVY is the first and only FDA-approved treatment for DB.¹,²

 

  • Simple to use: Just one drop per eye, twice a day, approximately 12 hours apart, for 6 weeks.
  • Clinically proven: In two combined studies, 50% of patients saw a reduction in crusties (collarettes), while 60% had their Demodex mites completely eliminated.³*
  • Designed for comfort: Approximately 90% of patients in both trials reported that XDEMVY eye drops were neutral to very comfortable to use.³†

    Stay on Top of Your Treatment

    For the best results, it’s essential to complete the full 6-week treatment.

    Reduce Eyelid Redness

    Patients using XDEMVY for DB may notice their eyelid redness significantly reduced—possibly gone—in just 6 weeks.¹²

To receive more information about this treatment you can make an appointment or call us at the clinic.

 

 

References: 1. Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. Clin Optometry. 2018;10:57-63. 2. Rhee MK, Yeu E, Barnett M, et al. Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens. 2023;49(8):311-318. 3. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153-1164. 4. O’Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of Demodex blepharitis. Clin Ophthalmol. 2022;16:2979-2987.
XDEMVY for Demodex blepharitis was evaluated in 2 pivotal trials of 833 patients (415 received XDEMVY).2,4,5
Trial 1: When taken twice daily in each eye for 6 weeks, XDEMVY reduced collarettes to 2 or less for the upper eyelid in 44% of patients (N=209) at Day 43; XDEMVY eradicated mites (mite density of 0 mites/lash) in 68% of patients (N=212) at Day 43.
Trial 2: When taken twice daily in each eye for 6 weeks, XDEMVY reduced collarettes to 2 or less for the upper eyelid in 55% of patients (N=193) at Day 43; XDEMVY eradicated mites (mite density of 0 mites/lash) in 50% of patients (N=203) at Day 43.
All visits averaged.3

This will close in 23 seconds